Clinical trial · Interventional
Intravesical Chemotherapy Treatment of Superficial Bladder Cancer
Intravesical Gemcitabine Therapy in Intermediate Risk Superficial Bladder Cancer: A Phase II Study With the Marker Lesion
NCT00491114CI-TRIAL-00000767completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a phase II study where chemotherapy (gemcitabine) is given into the urinary bladder.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Neoplasms | Bladder Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gemcitabine | Drug | Gemcitabine | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To evaluate the response rate
Secondary outcomes (2)
- measure
- To define the relapse free survival
- measure
- To assess toxicity profile
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Superficial bladder cancer * No prior chemotherapy Exclusion Criteria: * Grade 3 tumors * Papillary tumors invading connective tissue * Significant urologic disease, possible interfering with intravesical therapy
References
Publications (0)
Data not yet available
No reference posted for this study.